Audentes Therapeutics, Inc. (NASDAQ:BOLD) major shareholder Orbimed Advisors Llc sold 5,000 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $22.35, for a total value of $111,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Audentes Therapeutics, Inc. (BOLD) opened at 24.28 on Wednesday. Audentes Therapeutics, Inc. has a 52 week low of $13.13 and a 52 week high of $24.50. The stock’s market capitalization is $674.60 million. The company has a 50-day moving average price of $24.35 and a 200 day moving average price of $16.88.
Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.10). Equities analysts forecast that Audentes Therapeutics, Inc. will post ($3.53) EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN lifted its position in Audentes Therapeutics by 278.5% during the 1st quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 5,700 shares during the period. Nationwide Fund Advisors lifted its position in Audentes Therapeutics by 288.9% during the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 6,384 shares during the period. Citadel Advisors LLC acquired a new stake in Audentes Therapeutics during the 1st quarter worth about $184,000. State of Wisconsin Investment Board acquired a new stake in Audentes Therapeutics during the 2nd quarter worth about $210,000. Finally, Rhumbline Advisers acquired a new stake in Audentes Therapeutics during the 2nd quarter worth about $252,000. 77.01% of the stock is owned by institutional investors.
BOLD has been the topic of several recent research reports. Zacks Investment Research raised Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Monday, July 17th. ValuEngine raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Finally, Evercore ISI initiated coverage on Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Audentes Therapeutics has a consensus rating of “Hold” and an average target price of $22.40.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.